This Award Season, you too can walk the red carpet. ENTER BELOW for your chance to win a trip to the Emmys, including airfare and 2 nights and 3 days in Los Angeles for you and a guest.
Sweepstakes brought to you by Galderma, makers of Mirvaso® (brimonidine) topical gel, 0.33%*, the only FDA-approved treatment for the persistent facial redness of rosacea.
Important Safety Information Indication: Mirvaso® (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema, flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: Mirvaso Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome. Alpha-2 adrenergic agents can lower blood pressure. Mirvaso Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of Mirvaso Gel by children have been reported. Keep Mirvaso Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
*Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base.
About Beauty Banter Beauty Banter was launched in July of 2006 as a comprehensive beauty blog covering trends, tips and tricks, insider secrets, and weekly must-haves. Beauty Banter has a reputation of being on the cutting edge of emerging trends and product launches so our readers are always the first to know what’s hot and what’s just not.